Drug Profile
LY 3202328
Alternative Names: LY3202328Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Dyslipidaemias in USA (PO)
- 01 Feb 2017 Eli Lilly completes a phase I trial for Dyslipidaemias in USA (PO) (NCT02714569)
- 16 Mar 2016 Preclinical trials in Dyslipidaemias in USA (PO) before March 2016